G1 Therapeutics, Inc.
Morphic forms of trilaciclib and methods of manufacture thereof

Last updated:

Abstract:

An advantageous isolated morphic form of trilaciclib which is 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spir- o[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one, for example in the form of a di-hydrochloride salt or a dihydrochloride, dihydrate.

Status:
Grant
Type:

Utility

Filling date:

13 Nov 2020

Issue date:

27 Apr 2021